Continuous EX-4 treatment reduced the levels of COX1 (F(1,23) = 44.2042, p<0.001; Fig. 5B), COX2 (F(1,23) = 14.3844, p<0.01; Fig. 5C), NF-κB (F(1,23) = 4.5689, p<0.05; Fig. 5D), and CD45 (F(1,23) = 9.8604, p<0.01; Fig. 5E) against hyperglycemia and the CD45 level (F(1,23) = 20.9074, p<0.001; Fig. 5E) against intrahippocampal LPS injection. The gene discussed is PTPRC; the disease is Hyperglycemia.